ACP
ALPN

Acuta Capital Partners’s Alpine Immune Sciences Inc ALPN Stock Holding History

Acuta Capital Partners’s Portfolio ALPN Stock Details ALPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-230,000
Closed -$3.19M – 45
2021
Q4 		$3.19M Buy
+230,000
New +$2.85M 1.34% 26

Other funds holding ALPN

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acuta Capital Partners's ALPN Position: Q1 2022 in Review

Acuta Capital Partners sold out of Alpine Immune Sciences Inc (ALPN) in Q1 2022, closing a stake of 230,000 shares — an estimated $3.19M sold.

Acuta Capital Partners first reported a position in ALPN in Q4 2021 and held it in 1 quarter. The position peaked at $3.19M in Q4 2021. 56 funds tracked by Wall St. Rank hold ALPN as of Q1 2022.

  • Acuta Capital Partners reported no remaining Alpine Immune Sciences Inc position as of Q1 2022 after selling out during the quarter.
  • Acuta Capital Partners sold 230,000 Alpine Immune Sciences Inc shares in Q1 2022, an estimated $3.19M.
  • Acuta Capital Partners first reported a position in Alpine Immune Sciences Inc in Q4 2021 and held it in 1 quarter.
  • Acuta Capital Partners's Alpine Immune Sciences Inc position peaked at $3.19M in Q4 2021.
  • 56 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q1 2022.

Based on Acuta Capital Partners's 13F filing for Q1 2022, filed 16 May 2022.